PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Jun 5 2010

Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately. PEB's European licensee, Signature Diagnostics (SDX) completed the clinical trial and will present the results at the annual scientific meeting of the American Society of Clinical Oncology in Chicago on the 4^th of June.

“This prognostic gene signature for colorectal cancer is our second commercial product, and joins our bladder cancer diagnostic assay, Cxbladder™. Cxbladder™ is a fast, non-invasive assay that measures the activity of five genes from a small sample of the patient's urine to accurately diagnose bladder cancer.”

Chief Executive Officer David Darling stated that the conclusion of the European clinical trial was a significant commercial milestone for Pacific Edge. "This prognostic gene signature for colorectal cancer is our second commercial product, and joins our bladder cancer diagnostic assay, Cxbladder™. Cxbladder™ is a fast, non-invasive assay that measures the activity of five genes from a small sample of the patient's urine to accurately diagnose bladder cancer."

Pacific Edge Chief Scientific Officer Parry Guilford commented that the company's prognostic gene signature will meet a large unmet clinical need for patients diagnosed with stage II and stage III colorectal cancer. "Our prognostic gene signature identifies patients with stage II or III colorectal cancer whose disease is aggressive, likely to recur after surgery, and who would benefit from additional therapy."

Pacific Edge granted a European exclusive licence for its new cutting-edge prognostic gene signature for colorectal cancer to SDX in late 2006 with commercialisation pending a successful completion of the clinical trial. Europe is the second largest healthcare market in the world after the United States and represents around 30 per cent of global health care spending.